Return to Library
Stevens-Johnson syndrome and toxic epidermal necrolysis Visual Overview
Topic

Stevens-Johnson syndrome and toxic epidermal necrolysis

💡 What You Need to Know

  • Life-Threatening Reactions: Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe, potentially fatal mucocutaneous reactions.
  • Epidermal Detachment: Characterized by widespread blistering and detachment of the epidermis, resembling severe burns.
  • Drug-Induced: Most commonly triggered by medications, including certain antibiotics, anticonvulsants, NSAIDs, and allopurinol.
  • Spectrum of Severity: SJS involves less than 10% body surface area (BSA) detachment, TEN involves more than 30% BSA, and overlap syndrome is between 10-30%.
  • Medical Emergency: Requires immediate hospitalization, often in a burn unit or intensive care unit, for specialized care.

🤒 Associated Symptoms

  • Prodromal Phase: Often begins with fever, malaise, headache, cough, and flu-like symptoms 1-3 weeks after drug exposure.
  • Skin Lesions: Painful, rapidly spreading erythematous macules and atypical target lesions that progress to flaccid blisters and extensive epidermal sloughing.
  • Mucosal Involvement: Severe erosions and crusting affecting at least two mucosal sites (oral, ocular, anogenital), leading to difficulty eating, drinking, and vision impairment.
  • Nikolsky's Sign: Positive, meaning the epidermis can be easily detached from the dermis with gentle lateral pressure.
  • Systemic Manifestations: May include sepsis, acute kidney injury, respiratory distress, gastrointestinal bleeding, and liver dysfunction.

🛡 Crucial Precautions

  • Immediate Drug Withdrawal: Promptly discontinue all suspected causative medications upon diagnosis to halt disease progression.
  • Avoid Re-exposure: Patients must be educated to permanently avoid the identified culprit drug and chemically related compounds.
  • Genetic Screening: Consider HLA-B*1502 screening before prescribing carbamazepine to patients of Asian descent to reduce SJS/TEN risk.
  • Meticulous Skin Care: Implement sterile wound care techniques to prevent secondary infections, similar to burn management.
  • Fluid and Electrolyte Balance: Aggressive fluid resuscitation and electrolyte monitoring are critical due to extensive skin loss.

🍽 Dietary Directions & Restrictions

  • Nutritional Support: Due to severe oral and esophageal erosions, patients often require enteral (nasogastric or gastrostomy tube) or parenteral nutrition.
  • Intravenous Hydration: Maintain adequate hydration through intravenous fluids, especially in the acute phase, to compensate for significant fluid loss from denuded skin.
  • Soft, Bland Diet: Once oral intake is tolerated, introduce a soft, bland, non-acidic, and non-spicy diet to minimize irritation to healing mucosal lesions.
  • Avoid Irritants: Strictly avoid acidic, spicy, rough, or very hot foods and beverages that can exacerbate oral and esophageal discomfort.

⚠️ Attendant Guidelines

  • Specialized Unit Care: Patients should ideally be managed in a burn unit or intensive care unit with expertise in severe dermatological conditions.
  • Infection Prevention: Strict adherence to infection control protocols, including sterile dressing changes and systemic antibiotics for confirmed infections, is paramount.
  • Pain Management: Administer aggressive pain relief, often with opioids, to manage the severe pain associated with skin and mucosal lesions.
  • Ocular Care: Regular ophthalmology consultations and meticulous eye care (e.g., lubricating eye drops, topical corticosteroids) are essential to prevent long-term ocular complications.
  • Temperature Regulation: Monitor and manage body temperature carefully due to impaired thermoregulation from extensive skin loss.

🩺 Physician's Perspective

  • Early Diagnosis is Key: Rapid identification of SJS/TEN and immediate withdrawal of the offending drug are the most crucial interventions to improve prognosis.
  • Supportive Care Focus: Management is primarily supportive, concentrating on fluid and electrolyte balance, nutritional support, pain control, and prevention of infection.
  • Immunomodulatory Therapies: Systemic corticosteroids, intravenous immunoglobulin (IVIG), or cyclosporine may be considered, but their efficacy remains debated and timing is critical.
  • Prognostic Scoring: Utilize the SCORTEN score to assess mortality risk and guide management decisions.
  • Long-Term Follow-up: Patients require ongoing monitoring for potential sequelae, including chronic eye disease, skin scarring, pulmonary fibrosis, and psychological impact.

🎓 Academic & Nursing Corner

  • Comprehensive Assessment: Perform daily assessments of skin detachment percentage, mucosal involvement, and signs of infection.
  • Wound Management: Apply non-adherent dressings, perform gentle debridement of necrotic skin, and administer topical antimicrobials as prescribed.
  • Fluid Balance Monitoring: Accurately track intake and output, recognizing significant insensible fluid losses from denuded skin.
  • Patient Education: Educate patients and families about the causative drug, the importance of lifelong avoidance, and potential long-term complications.
  • Psychological Support: Provide empathetic care and psychological support to patients and families coping with a severe, disfiguring, and life-threatening condition.

🔬 Clinical Reference Index

  • Pathophysiology: Immune-mediated cytotoxic reaction leading to widespread keratinocyte apoptosis, often involving Fas-FasL pathway activation.
  • Common Causative Drugs: Sulfonamides, anticonvulsants (carbamazepine, lamotrigine, phenytoin), allopurinol, NSAIDs (oxicams), nevirapine.
  • Histopathology: Full-thickness epidermal necrosis with a sparse lymphocytic infiltrate at the dermo-epidermal junction.
  • Differential Diagnosis: Staphylococcal scalded skin syndrome (SSSS), generalized bullous fixed drug eruption, erythema multiforme major, acute generalized exanthematous pustulosis (AGEP).
  • SCORTEN Score Parameters: Age >40 years, presence of malignancy, heart rate >120 bpm, initial BSA detachment >10%, serum BUN >28 mg/dL, serum glucose >252 mg/dL, serum bicarbonate <20 mEq/L.